Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.


In a judgement that seems to chip the influential acumen that any form of hormone replacement psychotherapy raises the risk of breast cancer, a unheard of look at some old data suggests that estrogen-only hormone analysis might protect a mini subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone group therapy is actually protective" in women who have a stumpy risk for developing boob tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver rxlistbox.com. With his colleagues, Ragaz took another aspect at information from the Women's Health Initiative (WHI) study, a native venture that has focused on ways to avert knocker and colorectal cancer, as well as essence sickness and fracture risk, in postmenopausal women.



The body planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by front experts, far studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.



Two groups were neck of the woods of the try - women who had had hysterectomies and took estrogen singular as hormone replacement psychoanalysis and a faction that took estrogen advantage progestin hormone replacement therapy. The confederation treatment dry run was halted in 2002 after it became unconfused those women were at increased endanger for heart disease and breast cancer.



In the novel look at the estrogen-only group, Ragaz said, "we looked at women who did not have high-risk features". They found that women with no quondam narration of salubrious breast disease had a 43 percent reduction titty cancer risk on estrogen; women with no subdivision history with a first-degree relevant with breast cancer had a 32 percent chance reduction and women without previous hormone use had a 32 percent reduced risk.